LEAH Labs

LEAH Labs

We’re developing a cost effective cell therapy to cure cancer in dogs. It's proven in humans. We've built our MVP and showed it's safe in dogs. We treat cancer patients in August! We're a team of world leading experts in gene editing, immunotherapy, and veterinary oncology. We use CRISPR to genetically engineer T cells, making them cancer fighting machines. We’re backed by Y Combinator W19. Other alumni include Ginkgo Bioworks, Atomwise, Science Exchange.

Min investment
$100
Goal
$100K-$535K
Days Left
0
Location
Rochester, MN

CrowdLustro Research Report

Security Type
Other
Industry
Medical
Filed
March 15, 2021
Expires
April 30, 2021
Valuation Cap
$12M
Deal Structure

Future Equity Agreement (SAFE)

Management

Wesley Wierson, Chief Executive Officer
Genome hacker. Layla the mutt's dad. Gene editor since 2011. PhD in Molecular, Cellular, and Developmental Biology.

Alex Abel ,VP of Cell Biology
PhD in immunology. Rosie the Burnese's dad. Author of Natural Killer cell review read by nearly 100k scientists to date. Former technical sales at Miltenyi, world leader in cell biology applications.

Saad Kenderian, Scientific Founder - Immunotherapy
Physician scientist, hematologist, expert/inventor in CAR-T cell therapy. Developed tech for the first CAR-T IND approval at his institution. Assistant Professor, Medicine, Oncology

Deal Perks

  • $500+ Listed on LEAH Labs' website's "Wall of Wefunder Fame"
  • $2,500+ LEAH Labs Investor T-shirt
  • $5,000+ A 1 on 1 Zoom call with our Founder/CEO to discuss our business "behind the scenes"
  • $10,000+ If your dog ever needs our treatment (once commercially approved), a free dose of CAR-T cells to be administered by your vet.
  • $100,000+ A visit to our lab - flight, food, and lodging paid for (COVID-pending)

Research Reports

No reports have been submitted

Become a Reporter

0 Comments